Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER-4 adjuvant imlunestrant versus standard endocrine therapy in ER-positive, HER2-negative early breast cancer
MOH_2023-02-08_012343Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imlunestrant in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Efficacy of imlunestrant versus standard adjuvant endocrine therapy. Started Feb 2023; status: recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2023-02-08_012343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-08_012343.